Furadonin 100 mg tablets, No. 20 (10 x 2)

In stock: 1
$55.00

Composition

Active ingredient: nitrofurantoin;

1 tablet contains 100 mg of nitrofurantoin;

Excipients: potato starch, anhydrous colloidal silicon dioxide, calcium stearate.

Dosage Form

Tablets.

Main physical and chemical properties: round, flat tablets of yellow or greenish-yellow color with a beveled edge.

Pharmacotherapeutic group

Antibacterial agents. Nitrofuran derivatives.

ATX code J01X E01.

Pharmacological properties

Pharmacodynamics.

Nitrofurantoin is an antimicrobial agent of the nitrofuran group and a urinary antiseptic.

Its antimicrobial properties are due to nitrofurantoin’s ability to affect various enzymatic systems of microorganisms. Because of its high concentration in urine, nitrofurantoin is particularly effective in treating urinary tract infections.

Nitrofurantoin has a bacteriostatic effect (the drug is bactericidal at high concentrations).

The spectrum of antibacterial activity includes most microorganisms that cause urinary tract infections. Bacterial resistance to nitrofurantoin is rarely observed.

Microorganisms sensitive to nitrofurantoin include: Enterococci, Escherichia coli, Citrobacter spp., Group B Streptococci, Staphylococcus aureus, Staphylococcus epidermidis, as well as those that rarely cause urinary tract infections: Salmonella spp., Bacteroides spp., Streptococcus pneumoniae; moderately susceptible: Klebsiella pneumoniae, Enterobacter spp., Proteus spp., Providencia spp.; drug-resistant: Pseudomonas aeruginosa, Serratia spp., Proteus mirabilis, Pseudomonas cepacia, Acinetobacter spp.

Pharmacokinetics.

Nitrofurantoin is well absorbed in the gastrointestinal tract. Bioavailability is approximately 50% (food increases bioavailability). Plasma protein binding is 60–95%. It is partially metabolized in the liver. 30–50% of the dose is rapidly excreted unchanged in the urine, which explains the drug’s bacteriostatic and bactericidal effects in urinary tract infections. Effective therapeutic concentrations of nitrofurantoin in the blood and tissues are not achieved. The half-life is 0.5–1 hour. High concentrations of the drug in urine persist for up to 12 hours. Maximum serum concentration after a 100 mg dose is reached in 30 minutes. In cases of anuria or renal failure with a creatinine clearance below 45 mL/min, antibacterial concentrations of nitrofurantoin in the urine are not achieved, but the incidence of side effects increases. It crosses the placental and blood-brain barriers and is excreted into breast milk. The half-life is 0.3–1 hour.

Indications

Bacterial infections of the urinary tract (pyelitis, pyelonephritis, cystitis, urethritis), including for the treatment of recurrences, as well as for the prevention of infection during urological surgeries, catheterization, and cystoscopy.

Contraindications

  • Hypersensitivity to nitrofurantoin or the drug’s excipients;
  • Hypersensitivity to other nitrofurans;
  • pulmonary fibrosis;
  • pyelonephritis in the presence of concomitant inflammation of the renal parenchyma or a paranephric abscess;
  • anuria;
  • Oliguria;
  • porphyria;
  • renal failure (creatinine clearance less than 45 mL/min);
  • liver cirrhosis;
  • Chronic hepatitis;
  • Chronic heart failure;
  • Hemodialysis;
  • glucose-6-phosphate dehydrogenase deficiency (risk of hemolytic anemia);
  • neuritis and polyneuropathy;
  • pregnancy and lactation;
  • children under 12 years of age.

Interactions with Other Medications and Other Forms of Interaction

Nitrofurantoin should not be used in combination with medications that cause renal impairment.

Antacids and adsorbents reduce the absorption of the drug; therefore, their concurrent use with nitrofurantoin is not recommended.

Uricosuric agents (probenecid and sulfinpyrazone) reduce the excretion of nitrofurantoin (increasing its concentration in the blood, reducing its effectiveness, and increasing the risk of toxicity), therefore, their concurrent use with this drug is not recommended.

Carbonic anhydrase inhibitors reduce the drug’s antibacterial activity.

Nitrofurantoin reduces the reabsorption of estrogens.

When used concomitantly with contraceptives, the contraceptive effect may be reduced.

Nitrofurantoin inactivates the oral typhoid vaccine.

In vitro, nitrofurantoin reduces the antibacterial activity of quinolone drugs (nalidixic acid, fluoroquinolones). Concomitant use of these drugs should be avoided.

It should not be used concurrently with ristomycin, levomycetin, or sulfonamides, as this may suppress hematopoiesis.

In patients with renal insufficiency, the concurrent use of nitrofurantoin with aminoglycosides is not recommended.

When used concurrently with antibiotics (penicillins and cephalosporins), the antibacterial effect is significantly enhanced. The drug is well-tolerated when used with tetracycline and erythromycin.

The antibacterial effect of nitrofurantoin is reduced in alkaline urine; therefore, it should not be combined with drugs that increase urine pH.

Alcoholic beverages should not be consumed during treatment, as they may exacerbate undesirable side effects (e.g., headache, nausea, vomiting).

Special Considerations

According to some published data, the use of nitrofurantoin has been associated with acute attacks of porphyria; therefore, the drug is contraindicated in patients with porphyria.

Caution should be exercised in patients with impaired renal function. If urinary excretion of nitrofurantoin is reduced, therapeutic concentrations in the urine may not be achieved, which increases plasma concentrations and the risk of toxicity (if creatinine clearance is less than 45 mL/min, use is contraindicated).

No significant differences in response to nitrofurantoin treatment have been observed between elderly patients (over 65 years of age) and younger patients; however, caution is recommended due to the potential for renal insufficiency in the elderly.

Cases of pseudomembranous colitis have been reported during treatment with nitrofurantoin. The possibility of this adverse reaction should be kept in mind in patients with diarrhea caused by suppression of the natural microflora of the rectum during the use of antibacterial agents. In cases of mild pseudomembranous colitis, discontinuation of the antibacterial agent is sufficient; in cases of moderate to severe pseudomembranous colitis, appropriate treatment should be administered.

Caution should be exercised in patients with anemia, diabetes mellitus, electrolyte imbalance, malnourished patients, those with B-vitamin and folic acid deficiencies, lung disease, liver failure, or a predisposition to peripheral neuropathy.

If signs of peripheral neuropathy appear, the drug should be discontinued.

During long-term therapy, lung function should be monitored, especially in elderly patients, in whom pulmonary responses may be impaired. The drug should be discontinued at the first signs of lung involvement.

During long-term therapy, blood counts and liver function tests should be monitored. Nitrofurantoin may cause a false-positive result for glucose in urine when the copper reduction method is used.

If an enzymatic method is used to determine glucose in urine, the use of nitrofurantoin does not affect the test results.

The drug stains urine dark yellow or brown.

Hepatotoxicity.

Liver reactions, including hepatitis, autoimmune hepatitis, cholestatic jaundice, and chronic active hepatitis, can be insidious; therefore, patients should undergo periodic biochemical tests to monitor liver health. In the event of hepatitis, the drug should be discontinued immediately and appropriate measures taken.

Nitrofurantoin should not be used to treat diseases of the renal cortex, purulent paranephritis, or prostatitis.

Use of this medication may lead to diarrhea caused by Clostridium difficile. Treatment with this medication alters the normal microflora of the colon and promotes excessive growth of Clostridium difficile. If diarrhea caused by Clostridium difficile is suspected or confirmed, treatment with nitrofurantoin should be discontinued and appropriate treatment initiated.

In rare cases, bacterial resistance may develop during treatment with nitrofurantoin (especially with prolonged use). If resistance occurs, nitrofurantoin should be discontinued and another antibacterial agent selected for further treatment.

Pregnancy and lactation.

This medication is contraindicated during pregnancy or lactation.

Effects on the ability to operate vehicles and machinery.

Furadonin does not affect reaction time while driving or operating machinery; however, individuals experiencing dizziness, headache, or other central nervous system side effects during treatment should exercise caution.

Directions for Use and Dosage

Furadonin should be taken orally, immediately after a meal, with plenty of water.

Acute infections: adults—100 mg twice daily for 7 days.

Severe chronic recurrent infections: adults—100 mg 3–4 times daily for 7 days.

If nausea occurs, the dose should be reduced or the medication discontinued.

For the prevention of urinary tract infections, the recommended dose is 100 mg at bedtime.

For adults, the maximum single dose is 300 mg, and the maximum daily dose is 600 mg.

In children 12 years of age and older, adult doses may be used for acute, uncomplicated urinary tract infections.

Patients with impaired liver and/or kidney function, elderly patients

There are no dosage data available for patients with impaired liver and/or kidney function or for elderly patients. However, the drug should be used with caution. Furadonin is contraindicated in patients with renal failure.

Surgical prophylaxis: 100 mg twice daily on the day of the procedure and for 3 days following the procedure.

If the next dose is missed, continue the treatment course at the previously prescribed doses.

Children

The drug may be used in children over 12 years of age.

Overdose

Symptoms: nausea, vomiting, headache, dizziness.

Nervous system disorders indicate elevated plasma concentrations of nitrofurantoin. The development of polyneuropathy is a consequence of the accumulation of nitrofurantoin and its metabolites; therefore, the risk of developing polyneuropathy increases in cases of renal insufficiency.

Treatment: discontinuation of the drug; consumption of large amounts of fluid to promote the excretion of nitrofurantoin in the urine; administration of enterosorbents, antihistamines, and B vitamins. Treatment is symptomatic. There is no specific antidote.

In cases of acute overdose, gastric lavage should be performed.

Nitrofurantoin is removed by hemodialysis.

Side Effects

This medication may cause side effects, which do not occur in everyone.

Adverse reactions are listed according to the MedDRA system organ classification and by frequency: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000); unknown (cannot be estimated from the available data).

Infections and Infection-Related Conditions

Cases of pseudomembranous colitis have been reported during treatment with nitrofurantoin. In cases of mild pseudomembranous colitis, discontinuation of the drug is sufficient. In cases of moderate-to-severe pseudomembranous colitis, appropriate treatment should be administered.

Hematopoietic and Lymphatic Systems: Rarely—in patients with glucose-6-phosphate dehydrogenase deficiency, megaloblastic anemia, leukopenia, granulocytopenia, or agranulocytosis may develop, thrombocytopenia, and hemolytic anemia.

Immune system disorders: unknown—cutaneous vasculitis.

In isolated cases, autoimmune reactions have been observed, which are mainly associated with chronic changes in the lungs or liver. The main symptoms of this lupus-like syndrome are fever, a transient rash, arthralgia, and eosinophilia. Elevated serum levels are noted for antinuclear antibodies, antibodies to smooth muscle or renal glomeruli, and the Coombs test.

Neurological symptoms: common—headache; rare—drowsiness, dizziness, depression, euphoria, nystagmus, confusion, psychotic reactions, restlessness (agitation), asthenia, increased intracranial pressure, benign intracranial hypertension, peripheral neuropathy, the initial symptoms of which include paresthesias, burning sensation in the heels, and muscle weakness. If the first symptoms of peripheral neuropathy appear, treatment should be discontinued.

Diseases of the respiratory system, thorax, and mediastinum

Acute and chronic pulmonary hypersensitivity reactions are characterized by sudden fever, eosinophilia, cough, chest pain, and shortness of breath. Within a few hours or days after the start of therapy, pulmonary infiltrates or thickening and pleural effusion may occur, which resolve after discontinuation of the drug. With long-term therapy, patients may develop acute and subacute pulmonary symptoms, including pulmonary fibrosis. Pulmonary fibrosis may be irreversible, especially if therapy continues after symptoms appear. If the first symptoms of a pulmonary hypersensitivity reaction appear, the drug should be discontinued and appropriate treatment initiated.

Gastrointestinal system: common—nausea, vomiting, loss of appetite, anorexia (frequency and severity depend on the dose); rare—diarrhea, pancreatitis.  Side effects occur less frequently if the medication is taken with food and washed down with plenty of fluids.

Liver and/or biliary tract: rarely—hepatitis, cholestatic jaundice (dose-independent and resolves after discontinuation of the drug), cholestatic liver dysfunction; unknown – autoimmune hepatitis.

Skin and subcutaneous tissue disorders: common—hypersensitivity reactions (skin rashes, maculopapular rashes, urticaria, pruritus); rare—reversible hair loss;  in isolated cases, angioedema, inflammation of the salivary glands, exfoliative dermatitis, erythema multiforme (Stevens-Johnson syndrome), and lupus-like syndrome may occur.

Vascular disorders: rarely—flushing, circulatory collapse.

Renal and urinary tract disorders: frequency unknown—interstitial nephritis.

Musculoskeletal and connective tissue disorders: rare—gout, myalgia, joint pain.

Eye disorders: very rare—visual disturbances.

Reproductive system and breast disorders: very rare—transient disorders of spermatogenesis.

Other: Unknown – possible resistance to microorganisms such as Pseudomonas.

Shelf life

5 years.

Storage conditions

Store in a dry place, protected from light, at a temperature not exceeding 25 °C.

Keep out of reach of children.

Packaging

10 tablets per blister pack. 2 blister packs per cardboard box.

Conditions of Sale

By prescription only.

Manufacturer

Olainfarm, JSC.